• Users Online: 439
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
Year : 2016  |  Volume : 8  |  Issue : 6  |  Page : 335-342

First beneficial use of dapagliflozin for treatment of post-bariatric hypoglycemia: Case report and hypothesis

Center for Diabetes and Endocrinology, Institute of Medicine, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates

Correspondence Address:
Salem A Beshyah
Center for Diabetes and Endocrinology, Institute of Medicine, Sheikh Khalifa Medical City, Abu Dhabi
United Arab Emirates
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1947-489X.210247

Rights and Permissions

Background: Hypoglycemia is a significant complication of post-bariatric surgery. Case history: A 46 year old woman was referred for further management. She had had a Roux-en-Y gastric bypass surgery in 2012. She lost over 20 kilograms of weight. Pre-opertaively, a single HbA1c was borderline at 48 mmol/mol (6.5%) which improved to 41-44 mmol/mol. In November 2013, she started to experience symptoms suggestive of hypoglycemia. Dietary adjustments were advised and a trial of metformin and saxagliptin was given on basis of wide fluctuation of blood glucose with a remarkable early postprandial hyperglycemia followed by hypoglycemia. She stopped both medications due to gastrointestinal side effects. Renal and liver disease and hypoadrenalism were all excluded. We started her on increasing doses of Acarbose (an alpha glucosidase inhibitor) up to 100 mgs with each meal but she experienced minimal improvement in hypoglycemia. A a trial of Dapagliflozin, a sodiumglucose co-transporter 2 (SGLT 2) inhibitor, in a standard daily dose of 10 mgs in addition to Acarbose was offered to the patient (from 6th October 2015). The theoretical basis were explained to her and she consented verbally to this. Within 2 weeks, she experienced remarkable symptomatic improvement associated with reduction of both hyperglycemia and hypoglycemia documented on self-monitoring of blood glucose. The patient reduced Acarbose progressively to a complete cessation on her own accord. She remained well controlled solely on Dapagliflozin 10 mgs daily. The improvement is sustained for 12 months. The effect was further confirmed by 1 week off and one week on Dapagliflozin using flash glucose monitoring. Conclusions: This is the first report of a beneficial use of SGLT2 inhibition primarily for post-bariatric hypoglycemia. SGLT2 inhibitors may have a role in managing gastric bypass hypoglycemia.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded130    
    Comments [Add]    
    Cited by others 1    

Recommend this journal